Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $81.3M | $159M | $251M | $306M | $354M | $366M | $402M | $482M | $675M | $761M |
| Revenue growth | — | 95.8% | 57.8% | 22.0% | 15.5% | 3.4% | 9.8% | 20.0% | 39.9% | 12.8% |
| Operating income | $10.2M | $52.9M | $89.5M | $112M | $128M | $124M | $113M | $107M | $137M | $44.8M |
| Operating margin | 12.5% | 33.2% | 35.6% | 36.4% | 36.2% | 34.0% | 28.0% | 22.2% | 20.3% | 5.9% |
| Net income | $8.14M | $129M | $75.4M | $94.2M | $106M | $113M | $101M | $106M | $141M | $99.7M |
| Net margin | 10.0% | 81.1% | 30.0% | 30.7% | 30.0% | 30.7% | 25.2% | 22.0% | 20.9% | 13.1% |
| EPS (diluted) | $0.07 | $1.04 | $0.60 | $0.77 | $0.85 | $0.89 | $0.87 | $0.94 | $1.23 | $0.82 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $18.4M | $60.9M | $116M | $136M | $152M | $168M | $120M | $127M | $198M | $142M |
| Capital expenditures | $194K | $419K | $298K | $1.09M | $1.24M | $469K | $413K | $139K | $2.17M | $211K |
| Free cash flow | $18.2M | $60.5M | $115M | $135M | $151M | $167M | $120M | $127M | $196M | $142M |
| Share buybacks | $0.00 | $0.00 | $23.7M | $31.0M | $9.95M | — | $0.00 | $0.00 | $15.7M | $173M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $51.5M | $31.1M | $41.6M | $31.3M | $76.2M | $77.6M | $66.3M | $136M | $128M | $120M |
| Total assets | $68.8M | $221M | $312M | $412M | $572M | $424M | $583M | $622M | $841M | $837M |
| Total liabilities | — | $29.6M | $35.8M | $41.1M | $48.4M | $48.0M | $81.6M | $115M | $161M | $189M |
| Long-term debt | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Shareholders' equity | $41.4M | $191M | $276M | $371M | $523M | $376M | $502M | $507M | $680M | $648M |
| Retained earnings | -$322M | -$193M | -$118M | -$23.6M | $82.5M | $195M | $296M | $403M | $544M | $643M |
| Shares (wtd avg diluted) | 116M | 125M | 127M | 123M | 124M | 126M | 116M | 112M | 113M | 120M |
Every figure is extracted from CORCEPT THERAPEUTICS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.